|
|
Line 1: |
Line 1: |
| [[Image:2hob.jpg|left|200px]] | | {{Seed}} |
| | [[Image:2hob.png|left|200px]] |
|
| |
|
| <!-- | | <!-- |
Line 9: |
Line 10: |
| {{STRUCTURE_2hob| PDB=2hob | SCENE= }} | | {{STRUCTURE_2hob| PDB=2hob | SCENE= }} |
|
| |
|
| '''Crystal structure of SARS-CoV main protease with authentic N and C-termini in complex with a Michael acceptor N3'''
| | ===Crystal structure of SARS-CoV main protease with authentic N and C-termini in complex with a Michael acceptor N3=== |
|
| |
|
|
| |
|
| ==Overview==
| | <!-- |
| The viral proteases have proven to be the most selective and useful for removing the fusion tags in fusion protein expression systems. As a key enzyme in the viral life-cycle, the main protease (M(pro)) is most attractive for drug design targeting the SARS coronavirus (SARS-CoV), the etiological agent responsible for the outbreak of severe acute respiratory syndrome (SARS) in 2003. In this study, SARS-CoV M(pro) was used to specifically remove the GST tag in a new fusion protein expression system. We report a new method to produce wild-type (WT) SARS-CoV M(pro) with authentic N and C termini, and compare the activity of WT protease with those of three different types of SARS-CoV M(pro) with additional residues at the N or C terminus. Our results show that additional residues at the N terminus, but not at the C terminus, of M(pro) are detrimental to enzyme activity. To explain this, the crystal structures of WT SARS-CoV M(pro) and its complex with a Michael acceptor inhibitor were determined to 1.6 Angstroms and 1.95 Angstroms resolution respectively. These crystal structures reveal that the first residue of this protease is important for sustaining the substrate-binding pocket and inhibitor binding. This study suggests that SARS-CoV M(pro) could serve as a new tag-cleavage endopeptidase for protein overproduction, and the WT SARS-CoV M(pro) is more appropriate for mechanistic characterization and inhibitor design. | | The line below this paragraph, {{ABSTRACT_PUBMED_17189639}}, adds the Publication Abstract to the page |
| | (as it appears on PubMed at http://www.pubmed.gov), where 17189639 is the PubMed ID number. |
| | --> |
| | {{ABSTRACT_PUBMED_17189639}} |
|
| |
|
| ==About this Structure== | | ==About this Structure== |
Line 31: |
Line 35: |
| [[Category: Michael acceptor n3]] | | [[Category: Michael acceptor n3]] |
| [[Category: Sars-cov]] | | [[Category: Sars-cov]] |
| ''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Sun May 4 06:30:55 2008'' | | |
| | ''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Tue Jul 29 13:32:52 2008'' |